249 related articles for article (PubMed ID: 15972958)
21. Receptor-Activator of Nuclear KappaB Ligand Expression as a New Therapeutic Target in Primary Bone Tumors.
Yamagishi T; Kawashima H; Ogose A; Ariizumi T; Sasaki T; Hatano H; Hotta T; Endo N
PLoS One; 2016; 11(5):e0154680. PubMed ID: 27163152
[TBL] [Abstract][Full Text] [Related]
22. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation.
Quinn JM; Horwood NJ; Elliott J; Gillespie MT; Martin TJ
J Bone Miner Res; 2000 Aug; 15(8):1459-66. PubMed ID: 10934644
[TBL] [Abstract][Full Text] [Related]
23. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function.
Udagawa N; Takahashi N; Yasuda H; Mizuno A; Itoh K; Ueno Y; Shinki T; Gillespie MT; Martin TJ; Higashio K; Suda T
Endocrinology; 2000 Sep; 141(9):3478-84. PubMed ID: 10965921
[TBL] [Abstract][Full Text] [Related]
24. Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells.
Mancino AT; Klimberg VS; Yamamoto M; Manolagas SC; Abe E
J Surg Res; 2001 Sep; 100(1):18-24. PubMed ID: 11516200
[TBL] [Abstract][Full Text] [Related]
25. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor.
Gravallese EM; Manning C; Tsay A; Naito A; Pan C; Amento E; Goldring SR
Arthritis Rheum; 2000 Feb; 43(2):250-8. PubMed ID: 10693863
[TBL] [Abstract][Full Text] [Related]
26. Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulation.
Lai FP; Cole-Sinclair M; Cheng WJ; Quinn JM; Gillespie MT; Sentry JW; Schneider HG
Br J Haematol; 2004 Jul; 126(2):192-201. PubMed ID: 15238139
[TBL] [Abstract][Full Text] [Related]
27. Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts.
Takami M; Takahashi N; Udagawa N; Miyaura C; Suda K; Woo JT; Martin TJ; Nagai K; Suda T
Endocrinology; 2000 Dec; 141(12):4711-9. PubMed ID: 11108286
[TBL] [Abstract][Full Text] [Related]
28. Osteoblast lineage properties in giant cell tumors of bone.
Murata A; Fujita T; Kawahara N; Tsuchiya H; Tomita K
J Orthop Sci; 2005 Nov; 10(6):581-8. PubMed ID: 16307183
[TBL] [Abstract][Full Text] [Related]
29. Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint.
Haynes DR; Crotti TN; Loric M; Bain GI; Atkins GJ; Findlay DM
Rheumatology (Oxford); 2001 Jun; 40(6):623-30. PubMed ID: 11426018
[TBL] [Abstract][Full Text] [Related]
30. Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand.
Lee CK; Lee EY; Chung SM; Mun SH; Yoo B; Moon HB
Arthritis Rheum; 2004 Dec; 50(12):3831-43. PubMed ID: 15593184
[TBL] [Abstract][Full Text] [Related]
31. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions.
Quinn JM; Itoh K; Udagawa N; Hausler K; Yasuda H; Shima N; Mizuno A; Higashio K; Takahashi N; Suda T; Martin TJ; Gillespie MT
J Bone Miner Res; 2001 Oct; 16(10):1787-94. PubMed ID: 11585342
[TBL] [Abstract][Full Text] [Related]
32. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors.
Itoh K; Udagawa N; Matsuzaki K; Takami M; Amano H; Shinki T; Ueno Y; Takahashi N; Suda T
J Bone Miner Res; 2000 Sep; 15(9):1766-75. PubMed ID: 10976996
[TBL] [Abstract][Full Text] [Related]
33. Nuclear localization of type I parathyroid hormone/parathyroid hormone-related protein receptors in deer antler osteoclasts: evidence for parathyroid hormone-related protein and receptor activator of NF-kappaB-dependent effects on osteoclast formation in regenerating mammalian bone.
Faucheux C; Horton MA; Price JS
J Bone Miner Res; 2002 Mar; 17(3):455-64. PubMed ID: 11874237
[TBL] [Abstract][Full Text] [Related]
34. Interaction of Fas ligand and Fas expressed on osteoclast precursors increases osteoclastogenesis.
Park H; Jung YK; Park OJ; Lee YJ; Choi JY; Choi Y
J Immunol; 2005 Dec; 175(11):7193-201. PubMed ID: 16301623
[TBL] [Abstract][Full Text] [Related]
35. Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kappaB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha.
Kim HJ; Chang EJ; Kim HM; Lee SB; Kim HD; Su Kim G; Kim HH
Free Radic Biol Med; 2006 May; 40(9):1483-93. PubMed ID: 16632109
[TBL] [Abstract][Full Text] [Related]
36. Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones.
Ikeda T; Utsuyama M; Hirokawa K
J Bone Miner Res; 2001 Aug; 16(8):1416-25. PubMed ID: 11499864
[TBL] [Abstract][Full Text] [Related]
37. Identification and characterization of the precursors committed to osteoclasts induced by TNF-related activation-induced cytokine/receptor activator of NF-kappa B ligand.
Mochizuki A; Takami M; Kawawa T; Suzumoto R; Sasaki T; Shiba A; Tsukasaki H; Zhao B; Yasuhara R; Suzawa T; Miyamoto Y; Choi Y; Kamijo R
J Immunol; 2006 Oct; 177(7):4360-8. PubMed ID: 16982870
[TBL] [Abstract][Full Text] [Related]
38. Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro.
Spencer GJ; Utting JC; Etheridge SL; Arnett TR; Genever PG
J Cell Sci; 2006 Apr; 119(Pt 7):1283-96. PubMed ID: 16522681
[TBL] [Abstract][Full Text] [Related]
39. RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone.
Roux S; Amazit L; Meduri G; Guiochon-Mantel A; Milgrom E; Mariette X
Am J Clin Pathol; 2002 Feb; 117(2):210-6. PubMed ID: 11863217
[TBL] [Abstract][Full Text] [Related]
40. IL-3 acts directly on osteoclast precursors and irreversibly inhibits receptor activator of NF-kappa B ligand-induced osteoclast differentiation by diverting the cells to macrophage lineage.
Khapli SM; Mangashetti LS; Yogesha SD; Wani MR
J Immunol; 2003 Jul; 171(1):142-51. PubMed ID: 12816992
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
